Drug Resistance: Clinical Trials

3 trials for Drug Resistance, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 enrolling by invitation, 1 not yet recruiting. 3 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 43Completed 1, Enrolling by invitation 1, Not yet recruiting 1

Follow Drug Resistance: new trials by email Literature Review of Drug Resistance trials Research Report on Drug Resistance

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor
Rifaximin - ACS - Acute Coronary Syndrome, Ticagrelor
Phase 4Not yet recruitingCollegium Medicum w Bydgoszczy502026-01-012025-10-02
B-free Multistage Trial
DOR/DTG/3TC - HIV, Drug Resistance
Phase 4Enrolling by invitationInsel Gruppe AG, University Hospital Bern2102023-11-132024-12-04
Human Soil Transmitted Helminths (STH) Resistance to Benzimidazole in School Aged Children Living in Gabon
Benzimidazole Anthelmintic - Helminths Infection, Drug Resistance
Phase 4CompletedCentre de Recherche Médicale de Lambaréné2552019-11-112021-08-02

Narrower conditions

Acute Coronary Syndrome (1)  ·  Dysbiosis (1)  ·  Infections (1)  ·  Myocardial Infarction (1)

Broader conditions

Cardiovascular Diseases (1)  ·  Heart Diseases (1)  ·  Infarction (1)  ·  Ischemia (1)  ·  Myocardial Ischemia (1)  ·  Necrosis (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Vascular Diseases (1)

Interventions

Albendazole (1)  ·  Lamivudine (1)  ·  Mebendazole (1)  ·  Pyrantel (1)  ·  Rifaximin (1)  ·  dolutegravir (1)  ·  doravirine (1)

Sponsors

Centre de Recherche Médicale de Lambaréné (1)  ·  Collegium Medicum w Bydgoszczy (1)  ·  Insel Gruppe AG, University Hospital Bern (1)

Countries

Gabon (1)  ·  Poland (1)  ·  Switzerland (1)

Top investigators

Gilles Wandeler, Prof (1)  ·  Jacek Kubica, Prof. (1)

Results publications

PMID 38563751, PMID 39578038, PMID 41364144